Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1986-7-25
pubmed:abstractText
Several simple test methods that revealed alterations in mechanisms of action proved to be useful in the selection of three new anthracycline analogues that are currently in preclinical development. 5-Iminodaunorubicin is a quinone-modified analogue, and the resultant suppression of quinone redox cycling appears to correlate with diminished cardiotoxicity rather than with any effect on antitumour activity. N,N-Dibenzyldaunorubicin is an inactive prodrug requiring metabolic activation, a process that appears to give some selectivity of action leading to improved activity. The cyanomorpholino derivative of doxorubicin shows an intense potency against tumours that is not encountered in other closely-related analogues, indicating a highly specific mode of action as yet unidentified. Results with these examples suggest that simple tests related to mechanisms of action may be more useful for analogue selection than extended tests to define antitumour activity.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0378-6501
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Anthracycline mechanisms in analogue selection.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review, Research Support, Non-U.S. Gov't